Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Cancer|July 11, 2022
Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignanciesThomas A Ollila, Rebecca H Masel, John L Reagan, et al.
Experimental Hematology & Oncology|May 14, 2025
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite studyNarendranath Epperla, Geoffrey Shouse, Natalie S Grover, et al.
Cancer Research Communications|November 13, 2025
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Andre L De Souza, Matthew J Hadfield, Shaolei Lu, et al.
Stem Cells and Development|January 21, 2017
Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous LeukemiaAnna Chorzalska, Javier Flores Kim, Karim Roder, et al.
Molecular Oncology|February 28, 2018
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemiaAnna Chorzalska, Nagib Ahsan, R Shyama Prasad Rao, et al.
British Journal of Haematology|May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLDMarshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
Hematological Oncology|April 22, 2025
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort StudyPallawi Torka, Natalie S Grover, Timothy J Voorhees, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Blood Cancer Journal|October 18, 2024
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort studyNatalie S Grover, Kaitlin Annunzio, Marcus Watkins, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Pageof 13